1 reports of this reaction
6.3% of all MICONAZOLE NITRATE 2% reports
#3 most reported adverse reaction
CELLULITIS is the #3 most commonly reported adverse reaction for MICONAZOLE NITRATE 2%, manufactured by Akron Pharma Inc.. There are 1 FDA adverse event reports linking MICONAZOLE NITRATE 2% to CELLULITIS. This represents approximately 6.3% of all 16 adverse event reports for this drug.
Patients taking MICONAZOLE NITRATE 2% who experience cellulitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CELLULITIS is moderately reported among MICONAZOLE NITRATE 2% users, representing a notable but not dominant share of adverse events.
In addition to cellulitis, the following adverse reactions have been reported for MICONAZOLE NITRATE 2%:
The following drugs have also been linked to cellulitis in FDA adverse event reports:
CELLULITIS has been reported as an adverse event in 1 FDA reports for MICONAZOLE NITRATE 2%. This does not prove causation, but indicates an association observed in post-market surveillance data.
CELLULITIS accounts for approximately 6.3% of all adverse event reports for MICONAZOLE NITRATE 2%, making it one of the most commonly reported side effect.
If you experience cellulitis while taking MICONAZOLE NITRATE 2%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.